Capital Impact Advisors’s Kura Oncology KURA Stock Holding History

Capital Impact Advisors’s Portfolio KURA Stock Details KURA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-62,331	Closed	-$2.04M	–	121
2020 Q4	$2.04M	Hold	62,331	–	–	0.5%	79
2020 Q3	$1.91M	Hold	62,331	–	–	0.57%	83
2020 Q2	$1.02M	Sell	62,331 -78,374	-56%	-$1.13M	0.34%	103
2020 Q1	$1.4M	Buy	140,705 +8,361	+6%	+$95.7K	0.59%	83
2019 Q4	$1.82M	Buy	132,344 +10,071	+8%	+$149K	0.64%	93
2019 Q3	$1.8M	Buy	122,273 +20,075	+20%	+$357K	0.69%	89
2019 Q2	$2.02M	Sell	102,198 -34,569	-25%	-$574K	0.74%	49
2019 Q1	$1.84M	Hold	136,767	–	–	0.82%	37
2018 Q4	$1.84M	Buy	136,767 +40,415	+42%	+$535K	0.79%	40
2018 Q3	$1.68M	Hold	96,352	–	–	0.58%	98
2018 Q2	$1.67M	Buy	96,352 +16,600	+21%	+$281K	0.62%	97
2018 Q1	$1.5M	Buy	+79,752	New	+$1.55M	0.61%	80

Other funds holding KURA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Capital Impact Advisors's KURA Position: Q1 2021 in Review

Capital Impact Advisors sold out of Kura Oncology (KURA) in Q1 2021, closing a stake of 62,331 shares — an estimated $2.04M sold.

Capital Impact Advisors first reported a position in KURA in Q1 2018 and held it in 12 quarters. The position peaked at $2.04M in Q4 2020. 171 funds tracked by Wall St. Rank hold KURA as of Q1 2021.

Capital Impact Advisors reported no remaining Kura Oncology position as of Q1 2021 after selling out during the quarter.
Capital Impact Advisors sold 62,331 Kura Oncology shares in Q1 2021, an estimated $2.04M.
Capital Impact Advisors first reported a position in Kura Oncology in Q1 2018 and held it in 12 quarters.
Capital Impact Advisors's Kura Oncology position peaked at $2.04M in Q4 2020.
171 funds tracked by Wall St. Rank held Kura Oncology as of Q1 2021.

Based on Capital Impact Advisors's 13F filing for Q1 2021, filed 18 May 2021.